Review of Thymosin Alpha-1 Peptide Safety and Effectiveness Across 11,000 Patients

Across more than 30 clinical trials involving over 11,000 human subjects worldwide, thymosin alpha-1 demonstrated consistent safety and efficacy as an immune modulator. The peptide showed significant effectiveness in treating COVID-19 (improving immune function in severe cases), autoimmune conditions (restoring immune balance), and cancer (enhancing immune-mediated anti-tumor responses). No patterns of serious safety concerns emerged across the reviewed trials. The authors conclude the FDA's 2023 restriction on compounding pharmacies producing Tα1 is not supported by the clinical evidence base.

Narrative review with systematic search of PubMed, Google Scholar, and Cochrane Library for clinical trials involving thymosin alpha-1 in COVID-19, infectious diseases, cancer, and autoimmune diseases. The review analyzed outcomes from over 11,000 human subjects across more than 30 trials conducted worldwide.

Thymosin alpha-1 is one of the most extensively studied therapeutic peptides, with a long history of clinical use in over 30 countries (primarily as Zadaxin). The 2023 FDA restriction on compounding pharmacies producing Tα1 and other peptides generated significant controversy. This review compiles the clinical evidence to argue for continued access, directly addressing a major regulatory debate in the peptide therapeutics space.

The FDA's 2023 decision to restrict compounding of Tα1 and other peptides sparked intense debate about peptide access and regulation. While Tα1 is approved as a pharmaceutical in many countries, it never received FDA approval in the US and was available primarily through compounding pharmacies. This review represents the scientific community's response to the regulatory restriction, arguing that decades of clinical evidence support Tα1's safety and should be considered in regulatory decisions.

The review is described as a narrative review rather than a systematic review with strict inclusion criteria, which introduces potential selection bias. The authors advocate strongly for Tα1 availability, which may affect objectivity. Many of the included trials were conducted in countries with different regulatory standards. Publication bias — where positive results are more likely to be published — is a concern. The quality and design of the individual trials varies significantly.